Natalizumab (Tysabri) prior authorization at Premera Blue Cross
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Premera Blue Cross requires prior-authorization documentation for Natalizumab (Tysabri): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Premera Blue Cross reviews Natalizumab (Tysabri) prior authorizations against its medical policy . Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Premera Blue Cross's medical policy URL referenced in the cover letter
Premera Blue Cross's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- WA-specific mental health parity violations
- Step therapy via Express Scripts
- Out-of-network reductions
- Specialty drug prior auth
Natalizumab (Tysabri)-specific denial patterns and context
Across payers (not just Premera Blue Cross), Natalizumab (Tysabri)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- JC virus antibody index threshold restrictions
- Step therapy requiring oral DMT first
- Plan-mandated biosimilar switch (Tyruko approved 2023)
- Site-of-care reduction
Brand: Tysabri. α4-integrin antagonist for relapsing MS. REMS-restricted (TOUCH program) due to PML risk. Biosimilar Tyruko (natalizumab-sztn) FDA-approved August 2023 — plans now mandating switch.
Manufacturer patient-assistance program: Biogen Support Services — relevant when a Premera Blue Cross denial sticks and the patient needs bridge access while appealing.
How Premera Blue Cross approaches Biologic drugs (mAbs and biosimilars) PAs
Premera Blue Cross's Biologic drugs (mAbs and biosimilars) reviewer typically anchors Natalizumab prior-auth decisions on step therapy via express scripts and specialty drug prior auth. Pharmacy-benefit review for Natalizumab at Premera Blue Cross is routed through Express Scripts. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Premera Blue Cross's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Premera Blue Cross is domiciled in WA, so unresolved appeals escalate to the WA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee for Washington and Alaska (~2.
If the PA is denied
Premera Blue Cross gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.premera.com/wa/provider) with the same packet plus a peer-reviewed citation supporting Natalizumab (Tysabri)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Premera Blue Cross denial on DenialHelp.
Contact Premera Blue Cross
- Provider portal: https://www.premera.com/wa/provider
Frequently asked questions
What documentation does Premera Blue Cross need for Natalizumab (Tysabri) prior auth?
Premera Blue Cross's typical PA packet for Natalizumab (Tysabri): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Premera Blue Cross?
Standard Natalizumab (Tysabri) PA decisions at Premera Blue Cross: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Premera Blue Cross most often reject Natalizumab (Tysabri) for?
Across Premera Blue Cross's book the common rejection patterns include: WA-specific mental health parity violations; Step therapy via Express Scripts; Out-of-network reductions. For Natalizumab (Tysabri) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Premera Blue Cross typically require before approving Natalizumab?
Premera Blue Cross's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For Natalizumab, attach the specific disease-activity instrument Premera Blue Cross accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Premera Blue Cross fully-insured policies sits with the WA insurance department.
How do I prep for a peer-to-peer with Premera Blue Cross on Natalizumab (Tysabri)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Natalizumab (Tysabri) PA packet
Open ApprovalHelp — generate a Natalizumab (Tysabri) prior-auth packet tailored to Premera Blue Cross's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com